Femasys Inc
NASDAQ:FEMY
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Femasys Inc
Tax Provision
Femasys Inc
Tax Provision Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Tax Provision | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Femasys Inc
NASDAQ:FEMY
|
Tax Provision
-$1.3k
|
CAGR 3-Years
49%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Boston Scientific Corp
NYSE:BSX
|
Tax Provision
-$493m
|
CAGR 3-Years
-4%
|
CAGR 5-Years
-201%
|
CAGR 10-Years
N/A
|
|
|
Edwards Lifesciences Corp
NYSE:EW
|
Tax Provision
-$216.9m
|
CAGR 3-Years
-4%
|
CAGR 5-Years
-18%
|
CAGR 10-Years
-5%
|
|
|
Stryker Corp
NYSE:SYK
|
Tax Provision
-$1.3B
|
CAGR 3-Years
-57%
|
CAGR 5-Years
-29%
|
CAGR 10-Years
-16%
|
|
|
Abbott Laboratories
NYSE:ABT
|
Tax Provision
-$1.9B
|
CAGR 3-Years
-16%
|
CAGR 5-Years
-24%
|
CAGR 10-Years
-17%
|
|
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
Tax Provision
-$434.8m
|
CAGR 3-Years
-18%
|
CAGR 5-Years
-25%
|
CAGR 10-Years
-10%
|
|
Femasys Inc
Glance View
Femasys, Inc. operates as a medical device company that focuses on women's healthcare. The company is headquartered in Suwanee, Georgia. The company went IPO on 2021-06-18. The firm is focused on providing women worldwide with non-surgical product technologies, accessible in the office, improving patient care and overall health economics. The firm has two lead product candidates: FemBloc and FemaSeed. FemBloc is a permanent birth control solution in development. FemaSeed is an artificial insemination infertility treatment. The firm also offers FemVue Saline-Air device for diagnosis of infertility and FemCerv Endocervical Sampler for diagnosis of cervical cancer. FemCerv is a sterile, single-use disposable endocervical curettage product that can be used to sample cervical cells and tissue, including in support of further testing following an abnormal Pap test to assess for any problems such as cancer, in a relatively pain-free office procedure.
See Also
What is Femasys Inc's Tax Provision?
Tax Provision
-1.3k
USD
Based on the financial report for Dec 31, 2025, Femasys Inc's Tax Provision amounts to -1.3k USD.
What is Femasys Inc's Tax Provision growth rate?
Tax Provision CAGR 3Y
49%
Over the last year, the Tax Provision growth was 86%. The average annual Tax Provision growth rates for Femasys Inc have been 49% over the past three years .
